Organigram Global Inc. · TSX:OGI
Organigram Global — Q2 2026 Earnings Presentation
9 slides from Organigram Global's earnings presentation, May 12, 2026
Slide 1: Organigram Reports Second Quarter Fiscal 2026 Results
Organigram Reports Second Quarter Fiscal 2026 Results TORONTO, ON, May 12, 2026 - Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, is pleased to announce its results for the second quarter ended March 31, 2026 (“Q2 Fisca
Slide 2: Second Quarter Fiscal 2026 Financial Overview
◦ Adjusted gross margin was $18.4 million, or 31% of net revenue, compared to $21.9 million, or 33%, in Q2 Fiscal 2025. The year-over-year decrease in adjusted gross margin was primarily driven by changes in product mix, including a lower proportion of higher-margin product categories in the current
Slide 3: International Sales, Balance Sheet & Guidance
• In Q2 Fiscal 2026, Organigram generated $6.1 million in international sales, consistent with the prior year period. Performance reflected an elevated proportion of product that did not meet international specifications during the quarter. Sequentially, international sales increased from $5.0 milli
Slide 4: Select Key Financial Metrics
Select Key Financial Metrics Q2-2026 Q2-2025 % Change (in $000s unless otherwise indicated) Gross revenue 93,250 102,763 (9)% Excise taxes (33,456) (37,163) (10)% Net revenue 59,794 65,600 (9)% Cost of sales 44,800 45,813 (2)% Gross margin before fair value changes to biological assets & 14,994 19,7
Slide 5: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation Q2-2026 Q2-2025 (in $000s unless otherwise indicated) Net (loss) income as reported $ (921) $ 42,456 Add/(deduct): Investment income, net of financing costs (312) (179) Income tax expense (recovery) — (106) Depreciation and amortization 5,033 4,839 Impairment of proper
Slide 6: Free Cash Flow Reconciliation
Free Cash Flow Reconciliation Q2-2026 Q2-2025 (in $000s unless otherwise indicated) Net cash and restricted cash provided by (used in) operating activities $ (6,760) $ (16,585) Less: Purchase of property, plant and equipment (223) (6,508) Free Cash Flow (6,983) (23,093) Second Quarter Fiscal 2026 Co
Slide 7: Adjusted EBITDA and Adjusted Gross Margin Definitions
related to inventory and biological assets; government subsidies, insurance recoveries and other non-operating expenses (income); legal provisions (recoveries); ERP implementation costs; transaction costs; share issuance costs; and provision for Canndoc expected credit losses. Adjusted EBITDA is int
Slide 8: Forward-Looking Information
This news release contains forward-looking information. Forward-looking information, in general, can be identified by the use of forward-looking terminology such as “outlook”, “objective”, “may”, “will”, “could”, “would”, “might”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “con
Slide 9: Additional Forward-Looking and SEC Information
Commission (“SEC”) from time to time on the SEC’s Electronic Document Gathering and Retrieval System (“EDGAR”) at www.sec.gov, including the Company’s most recent management discussion and analysis ("MD&A") and annual information form. Readers are cautioned not to place undue reliance on these forwa